🧬 Endocrinology Update: GLP-1 Beats Metformin, Susvimo , AI Flags Hypoglycemia & More
This week’s endocrinology insights are redefining standards across diabetes, PCOS, osteoarthritis, and metabolic health. From landmark drug approvals to AI-driven risk detection, these are the headlines shaping tomorrow’s clinical decisions.
📌 In This Episode:
✔️ GLP-1 receptor agonists reduce cardiovascular risk in PCOS more effectively than metformin, cutting arrhythmias by 17 percent and thrombotic events by 22 percent.
✔️ FDA approves Susvimo as the first continuous delivery treatment for diabetic retinopathy, with over 80 percent of patients seeing significant improvement.
✔️ Bromocriptine shows strong potential in T2D management, lowering HbA1c and fasting glucose in a meta-analysis of 18 randomized trials.
✔️ High-riding patella identified in ACL-reconstructed knees is linked to increased risk of osteoarthritis due to altered joint mechanics.
✔️ Orforglipron, an oral GLP-1 therapy, demonstrates powerful effects on blood sugar control and weight loss—without injections.
✔️ A gestational diabetes care redesign in the Netherlands led to 85 percent fewer referrals, 47 percent less insulin use, and 10 percent lower costs.
✔️ ABSI (A Body Shape Index) is associated with nearly double the risk of osteoporosis in individuals in the highest risk quartile.
✔️ TyG-based insulin resistance indices are linked to knee osteoarthritis in T2D patients, while HOMA-IR shows no significant association.
✔️ Machine learning uncovers top hypoglycemia risk factors in T2D: insulin therapy, longer diabetes duration, and low kidney function.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology, diabetes, PCOS, osteoporosis, and more
#Endocrinology #DiabetesCare #GLP1 #PCOS #Susvimo #Bromocriptine #Orforglipron #T2D #GDM #Osteoporosis #MachineLearning #MetabolicHealth #HealthcareInnovation #LucidQuest #LQVentures #ClinicalUpdates #DigitalHealth